Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice

American Heart Journal

Volumn 142, Issue 2, 2001, Pages S9-S15

  Turpie, Alexander G G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THROMBIN INHIBITOR; WARFARIN;

ADULT; AGED; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; MALE; ORTHOPEDIC SURGERY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTITHROMBIN III; ARTHROPLASTY, REPLACEMENT, HIP; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; INJECTIONS, SUBCUTANEOUS; OLIGOSACCHARIDES; RANDOMIZED CONTROLLED TRIALS; VENOUS THROMBOSIS;

EID: 0034916051     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.117032     Document Type: Article

References (21)

1. Two new factors in blood coagulation: Heparin and pro-antithrombin
2. The inhibition of blood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin
3. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urologic surgery
4. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
5. Studies on the hemorrhagic agent 3,3′-methylenebis (4-hydroxycoumarin). I: Its effect on the prothrombin and coagulation time of the blood of dogs and humans
6. A preparation from spoiled sweet clover [3,3′-methylene-bis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: Preliminary report of experimental and clinical studies
7. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals from the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association
8. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
9. Starting prophylaxis for venous thromboembolism postoperatively
10. SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent
11. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR90107A/ORG31540)
12. Structure and biological activity of heparin
13. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes
14. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
15. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
16. First synthetic carbohydrates with the full anticoagulant properties of heparin
17. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics
18. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity
19. A synthetic pentasaccharide for the prevention of thrombosis after total hip replacement
20. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation